### General description

<table>
<thead>
<tr>
<th>INN</th>
<th>Amikacin</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>J01GB06</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>Antibiotic groups</td>
<td>ACCESS</td>
</tr>
</tbody>
</table>
| EML status history | First added in 1999 (TRS 895) for Multi-drug resistant Mycobacterium tuberculosis  
Added in 2017 (TRS 1006) for Sepsis without septic shock  
Added in 2017 (TRS 1006) for Neutropenia  
Added in 2017 (TRS 1006) for Acute pyelonephritis  
Added in 2017 (TRS 1006) for Inflammatory and other diseases of prostate  
Changed in 2021 (TRS 1035) for Infectious blepharitis  
Changed in 2021 (TRS 1035) for Other specified conjunctivitis |
| Therapeutic equivalent for | gentamicin for Infectious blepharitis  
gentamicin for Other specified conjunctivitis |
| Wikipedia    | Amikacin   |
| DrugBank     | Amikacin   |
Section  Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neutropenia (high-risk)

go-prescribed with cefotaxime

Inflammatory and other diseases of prostate (severe)

go-prescribed with cefotaxime

Acute pyelonephritis (severe)

go-prescribed with ceftriaxone

Inflammatory and other diseases of prostate (severe)

go-prescribed with ceftriaxone

Acute pyelonephritis (severe)

Second choice

co-prescribed with cloxacillin

Sepsis without septic shock

Section  Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

Multi-drug resistant Mycobacterium tuberculosis